Source link : https://www.newshealth.biz/health-news/big-pfs-increase-in-advanced-neuroendocrine-tumors-with-combination-therapy/
SAN FRANCISCO — Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline Depot) to everolimus (Afinitor), a study from Japan showed. Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three […]
Author : News Health
Publish date : 2025-01-21 22:33:52
Copyright for syndicated content belongs to the linked Source.
Categories